Skip to main content

Table 1 Logistic regression assessing correlation between PTC GL-3 reductions and GSRS-D improvement (patients with amenable mutations)

From: Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial

Parameter and Criteria

Odds Ratio

95% CI of Odds Ratio

GSRS-D Reduction From Baseline of 0.33 (n = 50)



p = .031

Kidney Peritubular Capillary GL-3 Reduction From Baseline > 0.1

  1. CI confidence interval, GL-3 globotriaosylceramide, GSRS-D Gastrointestinal Symptoms Rating Scale—diarrhea